Iron deficiency is common, and intravenous iron supplementation
|
|
- Holly Norris
- 5 years ago
- Views:
Transcription
1 Can the Response to Iron Therapy Be Predicted in Anemic Nondialysis Patients with Chronic Kidney Disease? Simona Stancu,* Liliana Bârsan, Ana Stanciu, and Gabriel Mircescu* *Department of Nephrology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; and Dr. Carol Davila Teaching Hospital of Nephrology, Bucharest, Romania Background and objectives: Anemia is iron responsive in 30 to 50% of nondialysis patients with chronic kidney disease (CKD), but the utility of bone marrow iron stores and peripheral iron indices to predict the erythropoietic response is not settled. We investigated the accuracy of peripheral and central iron indices to predict the response to intravenous iron in nondialysis patients with CKD and anemia. Design, setting, participants, & measurements: A diagnostic study was conducted on 100 nondialysis patients who had CKD and anemia and were erythropoiesis-stimulating agent and iron naive. Bone marrow iron stores were evaluated by aspiration. Hemoglobin, transferrin saturation index (TSAT), and ferritin were measured at baseline and 1 month after 1000 mg of intravenous iron sucrose. Posttest predictive values for the erythropoietic response (>1-g/dl increase in hemoglobin) of peripheral and central iron indices were calculated. Results: The erythropoietic response was noted in a higher proportion in bone marrow iron-deplete than in iron-replete patients (63 versus 30%). Peripheral iron indices had a moderate accuracy in predicting response. The positive (PPV) and negative predictive values (NPV) were 76 and 72% for a TSAT of 15% and 74 and 70% for a ferritin of 75 ng/ml, respectively. In the final logistic regression model, including TSAT and ferritin, the chances of a positive response increased by 7% for each 1% decrease in TSAT. Conclusions: Because an erythropoietic response is seen in half of patients and even one third of those with iron-replete stores responded whereas peripheral indices had only a moderate utility in predicting response, the therapeutic trial to intravenous iron seems to be a useful tool in the management of anemia in nondialysis patients with CKD. Clin J Am Soc Nephrol 5: , doi: /CJN Iron deficiency is common, and intravenous iron supplementation is a recognized therapy of anemia in long-term hemodialysis patients (HD), especially in those who are treated with epoetin (1 6). Several studies suggested that iron deficiency evaluated by bone marrow iron examination is common also in predialysis patients with chronic kidney diseases (CKD). In the reported series, the prevalence of bone marrow iron depletion varied widely from 23 to 90% (7,8). The role of iron supplementation in nondialysis patients with CKD is much less clear than in HD patients, although studies have reported a positive response to intravenous iron even without concomitant epoetin administration in 38 to 68% of patients (9 12). The prediction of erythropoietic response is clinically important, because the conventional markers of iron status serum ferritin level and transferrin saturation index (TSAT) although simple and relatively inexpensive, are not highly accurate in predicting response to iron in this population (5,7,8,11), and the safety of intravenous iron is a matter of concern in patients with CKD (13,14). Moreover, there are no published Received June 30, Accepted November 12, Published online ahead of print. Publication date available at Correspondence: Dr. Gabriel Mircescu, Calea Grivitei 4, Bucharest, Romania. Phone/Fax: ; gmircescu@hotmail.com data relating iron stores, peripheral iron indices, and the response to intravenous iron. We conducted a study to investigate the accuracy of peripheral and central iron status indices to predict the response to intravenous iron in nondialysis patients who had CKD and anemia and were erythropoiesis-stimulating agent and iron naive. Materials and Methods Study Design This was a single-center diagnostic study with a duration of 3 months. In a 2-month run-in period, renal function, anemia, and the other admission criteria were assessed. At baseline, a bone marrow aspiration was performed, peripheral iron indices were evaluated, and 1000 mg of iron sucrose was administered intravenously in 5 days, irrespective of iron status. One month after the last intravenous iron dose, blood was drawn for hemoglobin (Hb) and peripheral iron index evaluation. The reference test was the erythropoietic response, defined as a 1-g/dl increase in Hb level. Index tests were central (bone marrow iron stores, vide infra) and peripheral iron indices (TSAT and serum ferritin). The study was approved by the Helsinki committee of the hospital. Selection Criteria Anemia, defined as a Hb 11.0 g/dl (three measurements in the previous 8 weeks with 2.5-g/dl difference between highest and lowest values) and stages 3 through 5 CKD and mean estimated GFR Copyright 2010 by the American Society of Nephrology ISSN: /
2 410 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 (egfr; abbreviated Modification of Diet in Renal Disease [MDRD] formula) (15) 60 ml/min per 1.73 m 2 (three measurements in the previous 8 weeks each separated by at least 1 week) were the inclusion criteria. Patients with any previous iron or erythropoiesis-stimulating agent therapy, active infectious conditions, cancer, iron overload (ferritin 800 ng/ml), blood transfusions and/or active bleeding within the preceding 3 months, hemolytic anemia, folate or vitamin B 12 deficiency, severe malnutrition (Subjective Global Assessment score of C on a scale of A through C) (16), or hypothyroidism were excluded. Similarly, patients with congestive heart failure (New York Heart Association class III or IV), severe uncontrolled high BP (systolic BP 190 mmhg and/or diastolic BP 115 mmhg), active liver disease (more than three times increase in alanine or aspartate amino transferase), uremic complications (pericarditis, polyneuropathy), severe hyperparathyroidism (intact parathyroid hormone 800 pg/ml), severe psychiatric disorders, or known hypersensitivity to any component of iron sucrose as well as those who were participating in other clinical trials or refused to sign an informed consent were not enrolled. Patients One hundred adults (age 18 yr) were selected from the patients who were admitted to a nephrology department during a 2-year period (Figure 1). Laboratory Tests Bone Marrow Parameters of Iron Status. Bone marrow was collected by aspiration from the sternum. The smears were prepared from marrow fragments, colored with Perls Prussian blue stain, and interpreted by a senior hematologist who had no knowledge of the patients iron status. Positive and negative controls were used for calibration. Additional slides from aspirate were prepared when necessary, and at least nine bone marrow particles were reviewed for a final diagnosis (17). The occurrence of siderotic granules in macrophages was Figure 1. Patient selection. graded on a scale from 0 to 6 (18). Patients with a score of 0 or 1 were considered iron deficient, those graded from 2 to 4 as having normal macrophage iron, and those graded from 5 to 6 as having macrophage iron overload. Erythroblasts with green-blue particles on Perls stain were defined as sideroblasts. According to the number of siderotic granules, sideroblasts were classified as type 0 (no granules), type 1 (one to three granules), or type 2 (three or more granules), and their percentages were computed (19). The pattern of bone marrow iron distribution was classified as normal (macrophage iron 2 to 4, sideroblasts in normal percentage), iron deficiency (macrophage iron 0 or 1, sideroblasts absent or in a very low percentage), iron overload (macrophage iron 5, sideroblasts in normal or increased percentage), and anemia of chronic inflammation (macrophage iron 5, sideroblasts absent or in very low percentage). The patients were classified according to bone marrow iron as deplete (bone marrow iron deficiency) or replete (normal iron stores, iron overload, or anemia of chronic inflammation). Peripheral Parameters of Iron Status. Serum ferritin and serum transferrin were measured by immunoturbidometric methods (Good Biotech, Taichung, Taiwan; Giesse Diagnostics, Rome, Italy) on an autoanalyzer Olympus AU400. Total serum iron-binding capacity was calculated as serum transferrin Serum iron was assessed by a colorimetric method (Giesse Diagnostics). TSAT was calculated as the percentage of serum iron from total serum iron-binding capacity. Other Parameters. C-reactive protein (CRP) was assessed by a high-sensitivity latex immunoturbidometric method (Giesse Diagnostics). Statistical Analysis Data are presented as mean SD, 95% confidence interval (95% CI), or median and interquartile range, according to their distribution. A t test, paired or not, Mann-Whitney, 2, or Wilcoxon test was used to compare groups, as required. Receiver operating characteristic (ROC) curves (20 22) were created using the erythropoietic response as reference test (dichotomous variable) and macrophage iron score, ferritin, and TSAT and their combination as continuous variables. The effect of combining tests (TSAT and ferritin) was tested according to Trieppi et al. (23). The diagnostic accuracy was evaluated by sensitivity and specificity. Posttest positive probability of response in case of a positive test and of a nonresponse in case of a negative test was calculated at various cutoff values (24,25). Because the reported prevalence of nondialysis patients who had CKD and responded to intravenous iron therapy varied between 38 and 68% (9 12), a prevalence of 40% was used to calculate the posttest probability of response. The relationship between the erythropoietic response (present versus absent) and relevant parameters was investigated by multivariable binominal logistic regression. Considering a probability of 50% for a 1-g/dl increase in Hb and a presumed clinically significant difference among groups of 10%, at least 27 patients per group would be required for a 95% probability and a power of 95%. Statistical analyses were performed with Analyze-it (Analyze-it Software, Ltd., Leeds, UK) and SPSS (SPSS Inc., Chicago, IL) packages.
3 Clin J Am Soc Nephrol 5: , 2010 Can Response to Iron Be Predicted? 411 Results One hundred patients were enrolled and accomplished the study. Median age was 62 years (range 24 to 84); 55% were older than 60 years. There was a slight male preponderance (55%). Vascular nephropathies and primary glomerulonephritis were main causes of CKD, whereas diabetic nephropathy was rare (43, 36, and 3%, respectively). Median egfr was 14 ml/ min per 1.73 m 2 (interquartile range 10 24); most patients were in stage 4 or 5 CKD (28 and 56%). Inflammation was highly prevalent, but nutritional status was good, because 60% of patients had a serum CRP 10 mg/l, whereas 65% had a Subjective Global Assessment score of A and 75% a serum albumin 4 g/dl (Table 1). Anemia was severe: the mean Hb was 8.99 g/dl, and in 70% of cases, the initial Hb was 10 g/dl. Bone marrow iron stores were depleted in 48% of patients. Using conventional cutoffs for peripheral iron indices (TSAT 20% and ferritin 100 ng/ ml), the proportions of patients below cutoff were 33, 31, and 17% for the combination of tests (TSAT 20% and ferritin 100 ng/ml), respectively. One month after 1000 mg of intravenous iron, the mean Hb attained was 10.0 g/dl, with a g/dl mean increase. Hb increased by 1 g/dl in 48% of patients. In univariable analysis, the responders were younger and a higher proportion were in stage 4 CKD, but otherwise their general characteristics were similar to those of the nonresponders (Table 1). A macrophage iron score of 1, reflecting deplete iron stores, was more frequent in responders than in nonresponders (63 versus 33%), whereas the opposite was true in the case of patients with bone marrow iron overload (a macrophage iron score 3): 6 versus 29%. The proportion of responders was twice as high in patients with iron-deplete versus iron-replete stores (63 versus 30%). Similarly, the peripheral iron indices were different. Median TSAT and ferritin were lower in responders. Using cutoff values of 20% for TSAT and 100 ng/ml for ferritin, the percentages of patients with lower than cutoff values were significantly higher in responders than in nonresponders: 50 versus 17%, 48 versus 15%, and 33 versus 2% for the combination of tests, respectively (Figure 2). The sensitivity and the specificity of central and peripheral iron indices to identify the erythropoietic response was similar and moderate. Areas under the ROCs were approximately 70% and did not differ from one test to another. The combination of TSAT and ferritin was not superior to each test in predicting response (Figure 3). When examining the accuracy of the central and peripheral iron indices to identify a positive erythropoietic response at different cutoff values, the sensitivity was low, whereas the specificity was high (i.e., nonresponders were better identified by a negative test; Table 2). The posttest PPV and NPV for response of peripheral iron indices were balanced at cutoffs of 15% for TSAT (mean 0.76 [95% Cl, 0.50 to 0.93] and 0.72 [95% Cl, 0.64 to 0.79]) and 75 ng/ml for ferritin (mean 0.74 [95% Cl, 0.46 to 0.92] and 0.70 [95% Cl, 0.62 to 0.77]). In the case of a low macrophage iron score, sensitivity and specificity were 60%, but the PPV was low (mean 0.55 [95% Cl, 0.40 to 0.69]), whereas the NPV was higher (mean 0.74 [95% Cl, 0.60 to 0.85]). The same was true when bone marrow iron stores (deplete versus replete) were examined. Inflammation had a low influence on both iron indices and response. Neither median CRP nor the proportion of patients with CRP 10 mg/l was different in responders as compared with nonresponders. No correlation was found between ferritin and CRP, and the proportions of responders were similar when evaluated at different CRP cutoffs (data not shown). In multivariable logistic regression analysis, the final model included only TSAT and ferritin and predicted 19% of the variability of the erythropoietic response (Table 3). Only TSAT made a significant contribution (i.e., the chances of response increased with 7% for each 1% decrease in TSAT). Discussion This is one of the largest studies to evaluate the accuracy of central and peripheral iron indices to predict the response to intravenous iron in nondialysis patients with CKD. It confirms that bone marrow iron stores are depleted in an important proportion of the nondialysis patients with CKD and anemia and brings further support to the therapeutic intravenous iron test, because the predictive values of iron indices are only moderate. Few data are available about the prevalence of iron deficiency in nondialysis patients with CKD, because the bone marrow examination the gold standard in iron deficiency diagnosis is seldom performed. On the basis of bone marrow examination, 48% of our patients had deplete iron stores, a lower percentage than reported by Silverberg and colleagues (9) (90%) but higher than in data reported by Rahman et al. (8) (23%). Part of this wide variation could be attributed to the method of examination. In the study by Silverberg and colleagues (9), the bone marrow iron evaluation was not detailed, Rahman et al. (8) used only the number of macrophage siderotic particles, and we used a more complex examination, involving not only macrophage iron but also sideroblasts; however, our data support a significant prevalence of deplete bone marrow iron stores in nondialysis patients with CKD in advanced stages, not very different from reports of HD patients who were on epoetin therapy (40 to 63%) (4,26). Bone marrow iron is almost never used for clinical decision in day-to-day practice, and decisions are instead based only on peripheral iron indices. Typical markers of iron deficiency and cutoff values used in HD patients are a TSAT 20% and a ferritin 100 ng/ml. Kidney Disease Outcomes Quality Initiative (KDOQI) recommend these levels also for nondialysis patients with CKD (1). The proportions of patients who were below these cutoffs in our study were 33, 31, and 17% for the combination of TSAT and ferritin, respectively. By comparison, in Third National Health and Nutrition Examination Survey (NHANES III) cohort, in nondialysis patients with CKD and anemia (GFR 30 ml), only 35% of women and 33% of men had both a TSAT 20% and a ferritin 100 ng/ml (27). The higher proportions in NHANES III cohort, despite a lower percentage of patients with stage 5 CKD, could indicate that these cutoffs are not
4 412 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 Table 1. Characteristics of patients, according to the response to intravenous iron IV (n 100) Characteristic All (n 100) Responders (n 48) Nonresponders (n 52) P a Age (years) mean SD yr (%) Male gender (%) Primary renal disease (%) 0.9 glomerulonephritis interstitial nephropathies ADPKD vascular disease diabetic nephropathy egfr (ml/min; median IQR ) 14 (10 24) 17 (11 24) 13 (8 25) 0.8 CKD stage (%) Body mass index (kg/m 2 ) mean SD to 25.0 (%) Subjective global assessment score A (% patients) Serum albumin (g/dl) mean SD serum albumin 4 g/dl (%) CRP (mg/l) median (IQR) 15 (6 30) 15 (7 41) 15 (6 25) mg/l (%) Hb (g/dl) mean SD g/dl (%) TSAT (%) median (IQR) 23 (13 30) 18 (10 25) 26 (22 32) % Serum ferritin (ng/ml) median (IQR) 176 (79 300) 114 (51 197) 230 ( ) ng/ml (%) TSAT 20% and ferritin 100 ng/ml (% patients) Macrophage iron score (% patients) Bone marrow iron deplete (%) Erythropoietic response (g/dl) Hb (at assessment) Hb Response defined as 1-g/dl increase in Hb. ADPKD, autosomal dominant polycystic kidney disease; IQR, interquartile range. a Iron deplete versus iron replete. appropriate and may falsely identify too many patients as being iron deficient (27). Given these uncertainties, we initiated iron therapy in all patients, irrespective of their bone marrow iron status or peripheral iron indices. We chose to give iron intravenously, not orally, because studies (11,28) suggested a benefit of the intravenous route in patients with
5 Clin J Am Soc Nephrol 5: , 2010 Can Response to Iron Be Predicted? 413 Figure 2. Percentages of positive peripheral or bone marrow iron tests, according to the response to 1000 mg of intravenous iron ( 1-g/dl increase in Hb) in 100 nondialysis patients with CKD. sferr, serum ferritin. *P Figure 3. Sensitivity and specificity of TSAT and serum ferritin (ferritin) and their combination (TSAT ferritin) and bone marrow iron (BM iron) to identify correctly a positive erythropoietic response ( 1-g/dl increase in Hb [ Hb]) to intravenous iron in 100 nondialysis patients with CKD (areas under the ROCs). The areas under the ROCs do not differ in the case of TSAT, ferritin, and BM iron, but TSAT ferritin area under the ROC is significantly lower than the other. *P 0.05 versus TSAT and ferritin. characteristics similar to our cohort (initial low Hb and GFR and lack of epoetin therapy). In addition, a recent metaanalysis showed a small but significant difference in Hb level favoring the intravenous iron route (29). After intravenous iron sucrose administration, a significant hematologic response was noted in the whole cohort: 48% had a 1-g/dl increase in Hb, and 26% of patients attained 11 g/dl Hb. A 1-g/dl increase in Hb after intravenous iron is a useful predictive test for a positive response to iron therapy, recommended by KDOQI (1) in case of discordant iron indices, a position sustained by the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) study results in HD patients (30). In nondialysis patients with CKD, the reported proportion of responders only to intravenous iron were 68% (9), 44% (10), 38% (11), and 39% (12). Thus, a 40% prevalence of responders in this population would be reasonable and could be safely used for the evaluation of posttest probability of response. Although at first look both peripheral and central iron indices could differentiate responders from nonresponders (Figure 2, Table 1), the areas under the ROCs were approximately 70%, reflecting a moderate clinical utility (Figure 3). Of note, even 30% of patients with adequate iron stores responded. Furthermore, when predictive values were examined at different cutoffs, only a TSAT 15% and a ferritin 75 ng/ml performed clinically better, predicting a positive response in 70% of cases and excluding a negative response in the case of a negative test with a probability of approximately 70%. These cutoff values are closer to limits of nondialysis patients with CKD than to those of HD patients, in accordance with Fishbane s (31) assumption. In logistic regression, the utility of peripheral and bone marrow iron indices was also moderate; because only TSAT and ferritin were retained in the final model, a 1% lower TSAT increased the response chances by 7%. This is in line with a recent analysis of NHANES data, in which the percentage of nondialysis patients with CKD and anemia had a decreasing trend in TSAT but not in serum ferritin quartiles (32). In other studies that investigated the relationship between iron indices and response in nondialysis patients with CKD, the prognostic value of TSAT and serum ferritin for the erythropoietic response was also of marginal clinical utility. In a study by Van Wyck et al. (11), these tests proved unhelpful, but patients had a higher egfr, the anemia was less severe, TSAT was lower, and ferritin was higher than in our cohort, which can partially explain the differences. Similarly, Silverberg and colleagues (9)
6 414 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 Table 2. Sensitivity, specificity, and the predictive values of peripheral and bone marrow indices to predict the erythropoietic response to intravenous iron in nondialysis patients with CKD Parameter Sensitivity Specificity Posttest Predictive Value a For Response if Test Positive For Nonresponse if Test Negative TSAT (%) (0.18 to 0.45) 0.90 (0.79 to 0.97) 0.68 (0.36 to 0.90) 0.66 (0.59 to 0.73) (0.33 to 0.62) 0.90 (0.79 to 0.97) 0.76 (0.50 to 0.93) 0.72 (0.64 to 0.79) (0.48 to 0.77) 0.80 (0.67 to 0.90) 0.68 (0.49 to 0.84) 0.77 (0.66 to 0.85) (0.61 to 0.87) 0.51 (0.37 to 0.65) 0.51 (0.39 to 0.62) 0.76 (0.59 to 0.88) Ferritin (ng/ml) (0.12 to 0.37) 0.94 (0.84 to 0.99) 0.72 (0.33 to 0.95) 0.65 (0.59 to 0.70) (0.27 to 0.56) 0.90 (0.79 to 0.97) 0.74 (0.46 to 0.92) 0.70 (0.62 to 0.77) (0.34 to 0.64) 0.82 (0.69 to 0.92) 0.65 (0.43 to 0.83) 0.71 (0.61 to 0.79) (0.42 to 0.71) 0.76 (0.63 to 0.87) 0.62 (0.43 to 0.79) 0.73 (0.62 to 0.82) (0.46 to 0.75) 0.69 (0.54 to 0.81) 0.56 (0.39 to 0.72) 0.72 (0.59 to 0.82) Bone marrow iron macrophage iron score (0.48 to 0.77) 0.67 (0.52 to 0.79) 0.55 (0.40 to 0.69) 0.74 (0.60 to 0.85) (0.18 to 0.45) 0.63 (0.48 to 0.76) 0.35 (0.19 to 0.56) 0.58 (0.47 to 0.68) (0.01 to 0.17) 0.71 (0.56 to 0.83) 0.12 (0.02 to 0.39) 0.53 (0.46 to 0.60) bone marrow iron stores (deplete versus replete) 0.63 (0.48 to 0.77) 0.67 (0.52 to 0.79) 0.56 (0.40 to 0.71) 0.73 (0.60 to 0.84) Data are presented as mean (95% Cl). a Pretest probability of response 0.4. Table 3. Relationship between the index test (a 1-g/dl increase in Hb) and the reference tests in a model of multivariable binary logistic regression analysis Variable a B SE Wald df P Exp(B) (95% CI) TSAT (0.88 to 0.98) Ferritin (0.99 to 1.00) Constant Cox and Snell R ( ; dif 2; P 0.001). a Variables entered on step 1: Gender, age, Hb, CRP, TSAT, ferritin, GFR, and bone marrow iron (deplete or replete). found no correlation among TSAT, ferritin, and the erythropoietic response, although 90% of patients were iron deplete, but the number of patients was low. More data are needed to clarify this issue. A 1-g/dl increase in Hb was noted in one third of our patients without deplete bone marrow iron stores. This is similar to data from HD patients in the DRIVE study (30), in which peripheral iron indices were also not reliable predictors of response. Given the reduced prognostic utility of peripheral iron indices and even of the bone marrow stores for a positive response, a therapeutic trial with 1000 mg of intravenous iron seems to be more useful, but its practice should be carefully weighed against the potential deleterious effect of iron (13,14). What are the limits of this study? The assessment of bone marrow iron stores was made by a qualitative method on an aspirate, and a recent study that used a quantitative method proved a strong relationship between iron stores and ferritin in HD patients (33). To overcome these, not only macrophage iron was considered but also the sideroblasts, and a sufficient number of slides were examined (17). Moreover, relationships were found between iron stores and response. The number of participants, also one of the highest reported, still may be too small, and the composition of patients is different from the other reported series by the low proportion of patients with diabetes, the distribution skewed toward advanced CKD stages, more severe anemia, and highly prevalent inflammation. The high prevalence of inflammation (60% with a CRP 10 mg/l) seems not unusual in patients with anemia and advanced CKD, because recent reports gave similar proportions (74%) (34). In other studies, a correlation was found between CRP and ferritin, because ferritin is an acute-phase reactant and its utility in guiding iron therapy was questioned (4,30,35 37). An influence of inflammation on the erythropoi-
7 Clin J Am Soc Nephrol 5: , 2010 Can Response to Iron Be Predicted? 415 etic response is not sustained by our data, because no correlation was found between CRP and iron indices, and, similar to HD patients (3), neither in univariable analysis nor in the logistic regression did the CRP level have any influence on the response. The initial Hb level was linked to the response to intravenous iron (7,9), a relationship that was not found in our study, probably because of the severity of anemia in our patients. Nevertheless, all these characteristics are commonly found in day-to-day practice, and even if they could generate some statistical biases, they should be considered in the clinical decision. Conclusions Half of nondialysis patients with CKD responded with a 1-g/dl increase in Hb one month after 1000 mg of intravenous iron. Because even one third of patients with iron-replete bone marrow stores responded, whereas iron indices had a moderate accuracy in predicting the response, the therapeutic intravenous iron trial seems to be a useful tool in the management of anemia in nondialysis patients with CKD. Acknowledgments Part of this research was supported by a grant from Anemia Working Group, Romania. Part of this work was presented as a poster at World Congress of Nephrology; May 22 through 26, 2009; Milan, Italy. Disclosures None. References 1. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: , Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK: The evaluation of iron status in hemodialysis patients JAmSoc Nephrol 7: , Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G: The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16: , Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft EC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26: , Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1: S9 S18, Hörl WH: Adjunctive therapy in anaemia management. Nephrol Dial Transplant 17: 56 59, Silverberg DS, MD, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27: , Rahman MM, Dutta PK, Hoque M, Khan MIH, Banik D, Dutta AK, Hasan MU, Yunus EB, Yunus ABM, Rahman MJ: Evaluation of iron status by bone marrow iron stain and correlation with serum profile in chronic kidney disease (CKD). Journal of Bangladesh College of Physicians and Surgeons 25: , Gotloib L, Silverberg D, Shostak A: Iron deficiency is a very common cause of anemia in chronic kidney insufficiency and can often be corrected with IV iron. J Nephrol 19: , Mircescu G, Gârneat ă L,Căpuçsă C, Ursea N: Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients. Nephrol Dial Transplant 21: , Van Wyck DB, Roppolo MO, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68: , Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ: Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19: , Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: , Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: , Levey AS, Greene T, Kusek JW: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: A0828, Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. Canada-USA (CANUSA). JAmSoc Nephrol 7: , Hughes DA, Stuart-Smith SE, Bain BJ: How should stainable iron in bone marrow films be assessed? J Clin Pathol 57: , Rath CE, Finch CA: Sternal marrow hemosiderin: A method for the determination of available iron stores in man. J Lab Clin Med 33: 81 86, Hansen H, Weinfeld A: Hemosiderin estimations and sideroblasts counts in the differential diagnosis of iron deficiency and other anemias. Acta Med Scand 165: , Altman DG, Bland JM: Diagnostic tests 1: Sensitivity and specificity. BMJ 308: 1552, Altman DG, Bland JM: Diagnostic tests 2: Predictive values. BMJ 309: 102, Altman DG, Bland JM: Diagnostic tests 3: Receiver-operating characteristics plots. BMJ 309: 188, Tripepi G, Jager KJ, Dekker FW, Zoccali C: Diagnostic methods 2: Receiver operating characteristic (ROC) curves. Kidney Int 76: , Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39: , van Stralen KJ, Stel1 VS, Reitsma JB, Dekker FD, Zoccali C, Jager KJ: Diagnostic methods I: Sensitivity, specificity, and other measures of accuracy. Kidney Int 75: , Fernández-Rodríguez AM, Guindeo-Casasús MC, Molero- Labarta T, Dominguez-Cabrera C, Hortal-Cascon L, Perez-
8 416 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 Borges P, Vega-Dýaz N, Saavedra-Santana P, Palop-Cubillo L: Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 34: , Hsu C-Y, McCulloch CE, Curham GC: Iron status and hemoglobin level in chronic renal insufficiency. JAmSoc Nephrol 13: , Panesar A, Agarwal R: Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis 40: , Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am J Kidney Dis 52: , Daniel W, Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: , Fishbane S: Iron management in nondialysis-dependent CKD. Am J Kidney Dis 49: , Fishbane S, Pollack S, Feldman HI, Joffe MM: Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey Clin J Am Soc Nephrol 4: 57 61, Rocha LA, Barreto DV, Barreto FC, Dias CB, Moysés R, Silva MR, Moura LA, Draibe SA, Jorgetti V, Carvalho AB, Canzianiet ME: Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol 4: , Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G: Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant 23: , Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: , Wish JB: Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1[Suppl 1]: S4 S8, Ford BA, Coyne DW, Eby CS, Scott MG: Variability of ferritin measurements in chronic kidney disease: Implications for iron management. Kidney Int 75: , 2008
Published Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationCJASN epress. Published on December 31, 2008 as doi: /CJN
CJASN epress. Published on December 31, 2008 as doi: 10.2215/CJN.03980808 Association of Markers of Iron Stores with Outcomes in Patients with Nondialysis-Dependent Chronic Kidney Disease Csaba P. Kovesdy,*
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationEffect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
NDT Advance Access published November 13, 2014 Nephrol Dial Transplant (2014) 0: 1 8 doi: 10.1093/ndt/gfu357 Original Article Effect of oral liposomal iron versus intravenous iron for treatment of iron
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationPredictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation
http://www.kidney-international.org & 2007 International Society of Nephrology original article Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low
More informationEffect of Anemia and Hyperhomocysteinemia on Mortality of Patients on Hemodialysis
Dialysis Effect of Anemia and Hyperhomocysteinemia on Mortality of Patients on Hemodialysis Muhammad Anees, 1 Asim Mumtaz, 2 Muhammad Ibrahim, 3 Seemab Mumtaz Shaheen, 4 Aneela Asghar 5 Original Paper
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationIron deficiency anemia in chronic kidney disease: Uncertainties and cautions
Scholarly Review Iron deficiency anemia in chronic kidney disease: Uncertainties and cautions Rajiv AGARWAL Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans
More informationTitle:Trends in Anemia Management in US Hemodialysis Patients
Author's response to reviews Title:Trends in Anemia Management in US Hemodialysis Patients 2004-2010 Authors: Dana C Miskulin (dmiskulin@tuftsmedicalcenter.org) Jing Zhou (jzhou9@jhmi.edu) Navdeep Tangri
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationDiagnostic methods 2: receiver operating characteristic (ROC) curves
abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationThe safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease
Kidney International, Vol. 64, Supplement 87 (2003), pp. S72 S77 The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease DANIEL A. BLAUSTEIN, MICHAEL
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationIntravenous Iron Does Not Affect the Rate of Decline of Residual Renal Function in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hemal Shah, Ashutosh Shukla, Abirami Krishnan, Theodore Pliakogiannis, Mufazzal Ahmad, Joanne M. Bargman, Dimitrios G. Oreopoulos Intravenous Iron Does Not
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationWORLD JOURNAL OF PHARMACOLOGICAL RESEARCH AND TECHNOLOGY Anemia in CKD: A Review
Review Article ISSN: 2347-4882 WORLD JOURNAL OF PHARMACOLOGICAL RESEARCH AND TECHNOLOGY Anemia in CKD: A Review Supriya Mor* 1, Prashant Mor 2, Anupama Diwan 1 1 School of Pharmaceutical Sciences, Apeejay
More informationTSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator
Southern California Renal Disease Council, Inc. ESRD Network 18 TSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator TSAT 6255 West Sunset blvd Los Angeles, California i 90028 11/24/2010
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationEffect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
Nephrol Dial Transplant (2015) 30: 645 652 doi: 10.1093/ndt/gfu357 Advance Access publication 13 November 2014 Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationThe safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients
Kidney International, Vol. 68 (2005), pp. 1801 1807 The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients BRUCE S. SPINOWITZ, MICHAEL H. SCHWENK, PAULA M. JACOBS, W.
More informationStudy of Management of anemia in Chronic Kidney Disease Patients
Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical
More informationEfficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia
Research Article Efficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia Diana Laila Ramatillah* 1, Syed Azhar Syed Sulaiman 1, Amer Hayat Khan 1, Ong Loke Meng 2,
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationFuture Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008
Future Direction of Anemia Management in ESRD Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 The Evidence Normal Hct Study and CHOIR demonstrate adverse outcomes in ESA patients with target Hgb
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationSerum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation
The Journal of International Medical Research 2011; 39: 1961 1967 Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation Y XU, XQ DING, JZ ZOU, ZH LIU, SH JIANG AND
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationORIGINAL ARTICLE. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease
32 Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease N Nand 1, S Venu 2, AR Deshmukh 2, R Mittal 2 ORIGINAL ARTICLE Abstract This study
More informationAppropriateness of anemia management in hemodialysis patients
Saudi Pharmaceutical Journal (2012) 20, 85 91 King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com PRACTICE REPORT Appropriateness of anemia management in hemodialysis
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAdvanced Level. Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen Jenkins RN, PGDip HE, MSc
Advanced Level European Dialysis and Transplant Nurses Association/ European Renal Care Association Understanding Iron Deficiency Anaemia in Chronic Kidney Disease Information at Advanced Level. Karen
More informationIntravenous iron therapy is required by almost all hemodialysis
Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients Response to IV Iron with Elevated Ferritin
More informationOPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi:10.1093/ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J.
More informationAmong patients with peritoneal dialysis dependent
CJASN epress. Published on March 29, 2006 as doi: 10.2215/CJN.01541005 Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized,
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationTHE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS
214 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(3):23-212 doi: 1.2478/rjdnmd-214-25 THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
More informationRenal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail et al. BMC Nephrology (2017) 18:345 DOI 10.1186/s12882-017-0688-1 CORRESPONDENCE Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease Ashraf Mikhail 1*, Christopher
More informationTransfusion Burden among Patients with Chronic Kidney Disease and Anemia
Transfusion Burden among Patients with Chronic Kidney Disease and Anemia Elizabeth V. Lawler,* Brian D. Bradbury, Jennifer R. Fonda,* J. Michael Gaziano,* and David R. Gagnon* *Massachusetts Veterans Epidemiology
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationMETHODS RESULTS. Patients
ORIGINAL ARTICLE Korean J Intern Med 2014;29:489-497 Ferritin as a predictor of decline in residual renal function in peritoneal dialysis patients Soon Mi Hur, Hye Young Ju, Moo Yong Park, Soo Jeong Choi,
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationThe FIND-CKD Study Background Study design (Results)
The FIND-CKD Study Background Study design (Results) The FIND-CKD Study An open-label, multicentre, randomized, 3 arm study comparing the 12-month efficacy and safety of Ferric carboxymaltose (FCM, Ferinject
More informationInternational Journal of Current Research in Chemistry and Pharmaceutical Sciences Volume 1 Issue: Pages: 20-28
International Journal of Current Research in Chemistry and Pharmaceutical Sciences www.ijcrcps.com Volume 1 Issue: 3 2014 Pages: 20-28 (p-issn: 2348-5213; e-issn: 2348-5221) REVIEW ARTICLE PREVALENCE OF
More informationIndian Journal of Basic and Applied Medical Research; June 2015: Vol.-4, Issue- 3, P
Original article: Evaluation of efficacy and tolerability of iron sucrose and iron dextran in chronic renal failure patients in a tertiary care teaching hospital Dr. Panchal Pavan J.,Dr. Desai Mira K.
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationEPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
PATIENT BLOOD MANAGEMENT DALLA TEORIA ALLA PRATICA 16 FEBBRAIO 2018 EPO e Ferro in Emodialisi: Il PBM al suo esordio Lucia Del Vecchio Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationWilliam E. Strauss *, Naomi V. Dahl, Zhu Li, Gloria Lau and Lee F. Allen
Strauss et al. BMC Hematology (2016) 16:20 DOI 10.1186/s12878-016-0060-x RESEARCH ARTICLE Open Access Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients
More informationPossible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases
Clin Exp Nephrol (2015) 19:1179 1183 DOI 10.1007/s10157-015-1110-6 ORIGINAL ARTICLE Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Nelson Kopyt DO, FASN, FACP Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Efficacy and Safety of Oral Ferric Maltol (FM) in Treating Iron-Deficiency Anemia (IDA) in Patients with Chronic Kidney Disease
More informationInternationally indexed journal
www.ijpbs.net Internationally indexed journal Indexed in Chemical Abstract Services (USA), Index coppernicus, Ulrichs Directory of Periodicals, Google scholar, CABI,DOAJ, PSOAR, EBSCO, Open J gate, Proquest,
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationMasatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health
176 J Occup Health, Vol. 54, 2012 J Occup Health 2012; 54: 176 180 Journal of Occupational Health Evaluation of Validity of the Urine Dipstick Test for Identification of Reduced Glomerular Filtration Rate
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Adv Ther (2013) 30:1007 1017 DOI 10.1007/s25-013-0063-y ORIGINAL RESEARCH Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study Peter Choi Mourad
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Study of Improvement in Quality of Life with Recombinant Erythropoietin in Chronic End Stage Renal Failure Patients. Ratna Palit 1 *,
More informationPredictive Factors for Withdrawal from Peritoneal Dialysis: A Retrospective Cohort Study at Two Centers in Japan
Advances in Peritoneal Dialysis, Vol. 33, 2017 Yasuhiro Taki, 1 Tsutomu Sakurada, 2 Kenichiro Koitabashi, 2 Naohiko Imai, 1 Yugo Shibagaki 2 Predictive Factors for Withdrawal from Peritoneal Dialysis:
More informationIron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD
Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.
More informationGuideline Summary NGC-6019
NGC banner Guideline Summary NGC-6019 Guideline Title (1) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. (2) 2007 update of hemoglobin target.
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationEarly Initiation of Dialysis Fails to Prolong Survival in Patients with End-Stage Renal Failure
J Am Soc Nephrol 13: 2125 2132, 2002 Early Initiation of Dialysis Fails to Prolong Survival in Patients with End-Stage Renal Failure JAMIE P. TRAYNOR,* KEITH SIMPSON,* COLIN C. GEDDES, CHRISTOPHER J. DEIGHAN,*
More informationLinear and logistic regression analysis
abc of epidemiology http://www.kidney-international.org & 008 International Society of Nephrology Linear and logistic regression analysis G Tripepi, KJ Jager, FW Dekker, and C Zoccali CNR-IBIM, Clinical
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationIs the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration rate in type 2 diabetic patients?
Diabetes Care Publish Ahead of Print, published online October 3, 2008 The MCQ equation in DM2 patients Is the new Mayo Clinic Quadratic (MCQ) equation useful for the estimation of glomerular filtration
More informationThe role of correction of anaemia in patients with congestive heart failure: A short review
European Journal of Heart Failure 10 (2008) 819 823 www.elsevier.com/locate/ejheart Review The role of correction of anaemia in patients with congestive heart failure: A short review Donald S. Silverberg
More informationClinical Policy: Ferumoxytol (Feraheme) Reference Number: CP.PHAR.165
Clinical Policy: (Feraheme) Reference Number: CP.PHAR.165 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationChanges in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
http://www.kidney-international.org & 11 International Society of Nephrology see commentary on page 265 Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate
More informationClinical Practice Guideline Anaemia of Chronic Kidney Disease
Clinical Practice Guideline Anaemia of Chronic Kidney Disease Final Version: June 2017 Review Date: June 2022 Authors: Dr Ashraf Mikhail Consultant Nephrologist, Abertawe Bro Morgannwg University Health
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationEvidence-based practice in nephrology : Meta-analysis
Evidence-based practice in nephrology : Meta-analysis Paweena Susantitaphong, MD,Ph.D 1-3 1 Associate Professor, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationRecombinant human erythropoietin (EPO) is an effective
Septicemia in Patients with ESRD Is Associated with Decreased Hematocrit and Increased Use of Erythropoietin Allen R. Nissenson,* Michelle L. Dylan, Robert I. Griffiths, Hsing-Ting Yu, and Robert W. Dubois
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationA randomized trial of intravenous and oral iron in chronic kidney disease
http://www.kidney-international.org 2015 International Society of Nephrology clinical trial see commentary on page 3 A randomized trial of intravenous and oral iron in chronic kidney disease Rajiv Agarwal
More informationClinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory
More informationStudy on quality of life of chronic kidney disease stage 5 patients on hemodialysis Gyawali M, Paudel HC, Chhetri PK, Shankar PR, Yadav SK
JMCJMS Research article Study on quality of life of chronic kidney disease stage 5 patients on hemodialysis Gyawali M, Paudel HC, Chhetri PK, Shankar PR, Yadav SK JF Institute of Health Science/LACHS Hattiban
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationPreoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD
Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More information